MPM Oncology Impact Management »

Natera shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Natera (NTRA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Natera

Tip: Access up to 7 years of quarterly data

All positions including Natera held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Natera by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $19M 175k 108.29
2024-03-31 $16M 172k 91.46

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Natera

Vanguard Group
BlackRock
BlackRock
Jpmorgan Chase & Co
Farallon Capital Management
Fred Alger Management
State Street Corporation
Duquesne Family Office
T. Rowe Price Associates
Massachusetts Financial Services
Citadel Advisors
Invesco
Geode Capital Management
Kynam Capital Management
Lord, Abbett & Co

View all funds holding Natera